| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 61,385 | 90,285 | ||
| Accounts receivable, net | 137,673 | 109,726 | ||
| Inventories, net | 196,667 | 191,464 | ||
| Prepaid expenses and other current assets | 6,930 | 8,088 | ||
| Total current assets | 402,655 | 399,563 | ||
| Property and equipment, net | 69,509 | 57,501 | ||
| Intangible assets, net | 491 | 527 | ||
| Goodwill | 3,530 | 3,530 | ||
| Deferred tax assets, net | 74,433 | 79,235 | ||
| Right-of-use assets | 9,271 | 8,961 | ||
| Deposits and other assets | 8,798 | 9,063 | ||
| Total assets | 568,687 | 558,380 | ||
| Current portion of deferred revenue | - | 143 | ||
| Accounts payable | 24,021 | 29,769 | ||
| Accrued expenses and other current liabilities | 28,827 | 43,902 | ||
| Current portion of long-term debt | 2,344 | - | ||
| Current portion of lease obligations | 1,298 | 1,127 | ||
| Total current liabilities | 56,490 | 74,941 | ||
| Long-term debt | 70,084 | - | ||
| Deferred revenue, net of current portion | 1,440 | 1,476 | ||
| Senior notes payable, net of discount | - | 73,397 | ||
| Lease obligations, net of current portion | 9,397 | 9,301 | ||
| End of term fee | - | 938 | ||
| Other non-current liabilities | 90 | 2 | ||
| Total liabilities | 137,501 | 160,055 | ||
| Common stock - voting, 0.0001 par value, 300,000,000 shares authorized, september 30, 2025 239,661,041 issued and 238,332,393 outstanding december 31, 2024 236,620,545 issued and outstanding | 24 | 24 | ||
| Treasury stock, at cost, 1,328,648 and 0 shares as of september 30, 2025 and december 31, 2024, respectively | 23,188 | 15,148 | ||
| Additional paid-in capital | 665,382 | 660,909 | ||
| Accumulated deficit | -211,032 | -247,460 | ||
| Total stockholders equity | 431,186 | 398,325 | ||
| Total liabilities and stockholders equity | 568,687 | 558,380 | ||
ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. (ADMA)